默克医药公司肺癌晚期临床实验大幅提高存活及无癌症病兆率
Merck’s lung cancer treatment, Ketruda, performed better than expected in a late-stage, Phase 3 trial which has “significantly improved overall survival and progression-free survival”.
Merck’s lung cancer treatment, Ketruda, performed better than expected in a late-stage, Phase 3 trial which has “significantly improved overall survival and progression-free survival”.